Jun. 11, 2014, 6:18 PM
- During a CNBC Fast Money appearance, Arena (ARNA) CEO Jack Lief was tight-lipped about rumors Belviq partner Eisai (ESALY) is interested in acquiring his company.
- Investors trying to read between the lines see reasons to be hopeful.
- Lief also mentioned Belviq prescriptions are seeing week/week growth.
Jul. 9, 2012, 10:56 AMArena Pharmaceuticals (ARNA +4.3%) rallies with the help of a Sunday Bloomberg column discussing potential M&A interest in the drug developer, thanks to recent FDA approval of its Belviq weight-loss drug. Analysts speculate GlaxoSmithKline (currently divesting a diet pill line) or Japan's Eisai (the U.S. launch partner for Belviq) could make a bid. 25.3% of Arena's float was shorted as of June 15. | 6 Comments
ARNA vs. ETF Alternatives
Arena Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.
Other News & PR